DARZALEX 1,800 mg solution for injection
- Name:
DARZALEX 1,800 mg solution for injection
- Company:
Janssen Sciences Ireland
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/01/21

Click on this link to Download PDF directly
Janssen Sciences Ireland
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 13 January 2021 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 13 January 2021 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Infections and infestations |
Pneumoniaa |
Very Common |
16 |
10 |
Bronchitisa |
17 |
2 |
||
Upper respiratory tract infectiona |
41 |
3 |
||
Urinary tract infection |
Common |
8 |
1 |
|
Influenza |
5 |
1* |
||
Sepsisa |
4 |
4 |
||
Cytomegalovirus infectiona |
1 |
<1* |
||
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
Updated on 20 August 2020 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Summary of the safety profile
The most frequent adverse reactions of any grade (≥20 % patients) with daratumumab (either intravenous or subcutaneous formulations) when administered either as monotherapy or combination treatment were IRRs, fatigue, nausea, diarrhoea, constipation, pyrexia, cough, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, sepsis, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.
…………………
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3-4 |
|||
Infections and infestations |
Upper respiratory tract infectiona |
Very Common |
38% |
2% |
Bronchitisa |
Very Common |
14% |
2% |
|
Pneumoniaa |
Very Common |
14% |
9% |
|
Urinary tract infection |
Common |
7% |
1% |
|
Influenza |
Common |
4% |
1%# |
|
Sepsisa |
Common |
4% |
3% |
………………………..
Infections
In patients receiving DARZALEX subcutaneous formulation as monotherapy, incidence of infections was similar between DARZALEX subcutaneous formulation (52.9%) versus intravenous daratumumab groups (50.0%). Additionally, Grade 3 or 4 infections also occurred at similar frequencies between DARZALEX subcutaneous formulation (11.7%) and intravenous daratumumab (14.3%). Most infections were manageable and rarely led to treatment discontinuation. Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies.
In patients receiving intravenous daratumumab combination therapy, Grade 3 or 4 infections were reported with intravenous daratumumab combinations and background therapies (as follows:
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; D‑VMP: 23%, VMP: 15%; DPd: 28%
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D‑VTd: 22%, VTd: 20%.).
Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In active controlled studies, Ddiscontinuations from treatment due to infections were reportedoccurred in 1-4% to 5% of patients. Fatal infections were generally balanced between the intravenous daratumumab containing regimens and active control arms (<2%) in the controlled studies and were primarily due to pneumonia and sepsis.
In patients receiving intravenous daratumumab combination therapy, fatal infections (Grade 5) were reported as follows:
Relapsed/refractory patient studies: DVd: 1%, Vd: 2%; DRd: 2%, Rd: 1%; DPd: 2%
Newly diagnosed patient studies: D-VMP: 1%, VMP: 1%; DRd: 2%, Rd: 2%; DVTd: 0%, VTd: 0%.
Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.
………………….
Elderly patients
Of the 3207 patients who received daratumumab (n=490 subcutaneous; n=2717 intravenous) at the recommended dose, 38% were 65 to 75 years of age, and 17% were 75 years of age or older. No overall differences in effectiveness were observed based on age. The incidence of serious adverse reactions was higher in older than in younger patients. Among patients with relapsed and refractory multiple myeloma (n=1827), the most common serious adverse reactions that occurred more frequently in elderly (≥65 years of age) were pneumonia and sepsis. Among patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (n=777), the most common serious adverse reaction that occurred more frequently in elderly (≥75 years of age) was pneumonia.
Updated on 20 August 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Common (may affect up to 1 in 10 people):
- irregular heart beat (atrial fibrillation)
- build up of fluid in the lungs making you short of breath
- flu
- urinary tract infection
- severe infection throughout the body (sepsis)
- dehydration
- high level of sugar in the blood
- low level of calcium in the blood
- inflamed pancreas
Updated on 23 July 2020 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
5.1 Pharmacodynamic properties
Immunogenicity
In patients treated with subcutaneous daratumumab in clinical trials, less than 1% of patients developed treatment-emergent anti-daratumumab antibodies. The incidence of treatment‑emergent anti‑daratumumab antibodies for DARZALEX subcutaneous formulation treatment was low, with 1 out of 451 patients tested positive for anti‑drug antibodies. The 1 patient in monotherapy that was positive for anti‑daratumumab antibody also had transient neutralising antibodies. There were no treatment‑emergent anti‑daratumumab antibody positive patients in combination therapies study. The anti‑daratumumab antibodies and neutralising antibodies did not appear to impact daratumumab exposures.
However, the employed assay has limitations in detecting anti‑daratumumab antibodies in the presence of high concentrations of daratumumab. Therefore, the incidence of antibody development might not have been reliably determined.
Updated on 23 July 2020 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 10 July 2020 Ed-Both
Reasons for updating
- Add New Doc
Updated on 10 July 2020 Ed-HCP
Reasons for updating
- Add New Doc
Updated on 10 July 2020 Ed-HCP
Reasons for updating
- Add New Doc
Updated on 11 June 2020 PIL
Reasons for updating
- New PIL for new product
Updated on 11 June 2020 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
New SmPC for new Product June 2020
Darzalex Patient CardRisk Minimisation Materials
(Click to Download)
Darzalex (daratumumab) Healthcare Professional CardRisk Minimisation Materials
(Click to Download)
Darzalex (daratumumab) Card for Haematology/Transfusion LaboratoryRisk Minimisation Materials
(Click to Download)
Educational Materials for Medicines
Educational Materials for Medicines
Darzalex Patient CardRisk Minimisation Materials
(Click to Download)
Educational Materials for Medicines
Educational Materials for Medicines